B7-H4 Activators
B7-H4 activators encompass a range of chemicals that directly or indirectly modulate the expression of B7-H4, an immune checkpoint molecule implicated in various physiological processes. Trichostatin A and 5-Aza-2'-deoxycytidine (Decitabine) are epigenetic modifiers that directly target histone deacetylases (HDAC) and DNA methyltransferases, respectively. Their actions induce changes in histone acetylation and DNA methylation, potentially impacting the epigenetic regulation of B7-H4 expression. Metabolic reprogramming is addressed by 2-Deoxy-D-glucose, an inhibitor of glycolysis, which indirectly influences B7-H4 by altering the metabolic environment. Signaling pathway inhibitors such as SB431542 (TGF-β receptor), BAY 11-7082 (NF-κB activation), Rapamycin (mTOR), PD0325901 (MEK), SB203580 (p38 MAPK), and AZD8055 (mTORC1/2) directly interfere with specific pathways associated with B7-H4 expression.
Epigenetic modulators like GSK126 (EZH2 inhibitor) and JQ1 (BET inhibitor) affect the histone methylation pattern and acetylation status, respectively, providing insights into the epigenetic control of B7-H4. NSC 319726, while not a direct activator, indirectly impacts B7-H4 through potential effects on DNA synthesis. This diverse array of chemicals provides a comprehensive overview of potential modulators of B7-H4 expression, shedding light on the intricate regulatory mechanisms that govern this immune checkpoint molecule. The direct and indirect mechanisms elucidated by these activators underscore the complexity of B7-H4 regulation, offering avenues for further exploration in understanding its role in immune responses and disease contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. It directly inhibits HDAC activity, leading to increased acetylation of histones. B7-H4 expression has been associated with epigenetic modifications. Trichostatin A, by inhibiting HDAC, induces hyperacetylation of histones, potentially influencing the epigenetic regulation of B7-H4 expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2'-deoxycytidine, also known as Decitabine, is a DNA methyltransferase inhibitor. It directly inhibits DNA methyltransferase, resulting in DNA demethylation. B7-H4 expression has been linked to DNA methylation patterns. Decitabine, by inhibiting DNA methyltransferase, induces DNA demethylation, potentially affecting the methylation status of the B7-H4 gene promoter. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a transforming growth factor-beta (TGF-β) receptor inhibitor. It directly inhibits TGF-β receptor activity. B7-H4 expression has been associated with TGF-β signaling. SB431542, by inhibiting TGF-β receptor, interferes with TGF-β-mediated pathways, potentially influencing B7-H4 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of nuclear factor-kappa B (NF-κB) activation. It directly inhibits IκBα phosphorylation, preventing NF-κB translocation to the nucleus. B7-H4 expression has been linked to NF-κB signaling. BAY 11-7082, by inhibiting NF-κB activation, interferes with NF-κB-mediated pathways, potentially influencing B7-H4 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a mammalian target of rapamycin (mTOR) inhibitor. It directly inhibits mTOR complex 1 (mTORC1) activity. B7-H4 expression has been associated with mTOR signaling. Rapamycin, by inhibiting mTORC1, interferes with mTOR-mediated pathways, potentially influencing B7-H4 expression. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
GSK126 is a selective enhancer of zeste homolog 2 (EZH2) inhibitor. It directly inhibits the activity of EZH2, a histone methyltransferase involved in H3K27 trimethylation. B7-H4 expression has been linked to H3K27 trimethylation. GSK126, by inhibiting EZH2, induces alterations in H3K27 trimethylation, potentially affecting the epigenetic regulation of B7-H4 expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a bromodomain and extra-terminal motif (BET) inhibitor. It directly inhibits the binding of BET proteins to acetylated histones. B7-H4 expression has been associated with BET proteins. JQ1, by inhibiting BET proteins, interferes with their binding to acetylated histones, potentially influencing B7-H4 expression. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR kinase activity. It directly inhibits mTOR complex 1 and 2 (mTORC1/2) activities. B7-H4 expression has been associated with mTOR signaling. AZD8055, by inhibiting mTORC1/2, interferes with mTOR-mediated pathways, potentially influencing B7-H4 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor. It directly inhibits the activity of p38 MAPK. B7-H4 expression has been associated with p38 MAPK signaling. SB203580, by inhibiting p38 MAPK, interferes with p38 MAPK-mediated pathways, potentially influencing B7-H4 expression. | ||||||
NSC 319726 | 71555-25-4 | sc-477736 | 10 mg | $159.00 | ||
NSC 319726 is a pyrimidine analog with potential antineoplastic activity. It may inhibit DNA synthesis. While not a direct activator, NSC 319726 indirectly influences B7-H4 through its impact on cellular processes such as DNA synthesis. By potentially interfering with DNA synthesis, NSC 319726 might indirectly modulate the regulatory mechanisms governing B7-H4 expression. | ||||||